CA2084659A1 - Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisations - Google Patents

Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisations

Info

Publication number
CA2084659A1
CA2084659A1 CA002084659A CA2084659A CA2084659A1 CA 2084659 A1 CA2084659 A1 CA 2084659A1 CA 002084659 A CA002084659 A CA 002084659A CA 2084659 A CA2084659 A CA 2084659A CA 2084659 A1 CA2084659 A1 CA 2084659A1
Authority
CA
Canada
Prior art keywords
hiv
vector
gene
nucleotides
sufficient number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002084659A
Other languages
English (en)
Inventor
Joseph G. Sodroski
William A. Haseltine
Marck Poxnansky
Andrew Lever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2084659A1 publication Critical patent/CA2084659A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • C12N2740/16052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002084659A 1990-06-20 1991-06-18 Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisations Abandoned CA2084659A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54074690A 1990-06-20 1990-06-20
US540,746 1990-06-20

Publications (1)

Publication Number Publication Date
CA2084659A1 true CA2084659A1 (fr) 1991-12-21

Family

ID=24156769

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002084659A Abandoned CA2084659A1 (fr) 1990-06-20 1991-06-18 Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisations

Country Status (4)

Country Link
EP (1) EP0536234A4 (fr)
JP (1) JP3264281B2 (fr)
CA (1) CA2084659A1 (fr)
WO (1) WO1991019798A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
ES2187504T3 (es) * 1992-02-28 2003-06-16 Syngenix Ltd Vectores no oncovirales, basados en el vmmp, con encapsidacion defectuosa.
WO1993020220A1 (fr) * 1992-03-27 1993-10-14 Whitehead Institute For Biomedical Research Particules de hiv non infectieuses et utilisations
EP0644946A4 (fr) * 1992-06-10 1997-03-12 Us Health Particules vecteurs resistantes a l'inactivation par le serum humain.
WO1994016736A1 (fr) * 1993-01-22 1994-08-04 University Research Corporation Localisation d'agents therapeutiques
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6200811B1 (en) * 1996-04-02 2001-03-13 The Regents Of The University Of California Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
CN1195863C (zh) * 1996-10-17 2005-04-06 牛津生物医学(英国)有限公司 逆转录病毒载体
PT1895010E (pt) 1997-12-22 2012-01-25 Oxford Biomedica Ltd Vectores com base no vírus da anemia infecciosa equina (eiav)
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
WO2001007646A2 (fr) * 1999-07-21 2001-02-01 Martin Heinkelein Procede de quantification de l'effet antiviral de principes actifs antiviraux
GB0108065D0 (en) * 2001-03-30 2001-05-23 Syngenix Ltd Viral vectors
CN1980955A (zh) * 2004-04-29 2007-06-13 北卡罗来纳-查佩尔山大学 增强细胞粘连特性的方法和组合物

Also Published As

Publication number Publication date
JP3264281B2 (ja) 2002-03-11
JPH05508320A (ja) 1993-11-25
EP0536234A1 (fr) 1993-04-14
WO1991019798A1 (fr) 1991-12-26
EP0536234A4 (en) 1993-09-15

Similar Documents

Publication Publication Date Title
US5665577A (en) Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5981276A (en) Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
CA2009403C (fr) Provirus hiv a encapsidation defectueuse, lignees cellulaires et leur utilisation
Parolin et al. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes
Chesebro et al. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages
Kondo et al. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles
Srinivasakumar et al. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines
Malim et al. Functional comparison of the Rev trans-activators encoded by different primate immunodeficiency virus species.
Bray et al. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent.
Sodroski et al. A second post-transcriptional trans-activator gene required for HTLV-III replication
Cheng-Mayer et al. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120
Kornfeld et al. Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses
Reitz Jr et al. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene
US6013516A (en) Vector and method of use for nucleic acid delivery to non-dividing cells
CA2084659A1 (fr) Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisations
Kim et al. V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate
US5747307A (en) Mason-Pfizer Monkey Retroviral packaging defective vectors
Etemad-Moghadam et al. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys
Foster et al. Specific suppression of human CD4 surface expression by Nef from the pathogenic simian immunodeficiency virus SIVmac239open
Ndung'u et al. Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model
Pfeiffer et al. Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells
Talbott et al. Mapping the determinants of human immunodeficiency virus 2 for infectivity, replication efficiency, and cytopathicity.
Wong-Staal The AIDS virus. What we know and what we can do about it.
EP0535161A4 (en) Expression vectors containing the hiv -i(nef) gene to enhance replication efficiency
Contag et al. Simian immunodeficiency virus (SIV) from Old World monkeys

Legal Events

Date Code Title Description
FZDE Discontinued